The estimated Net Worth of Louis Matis is at least $175 millier dollars as of 13 June 2016. Louis Matis owns over 10,000 units of Pieris Pharmaceuticals Inc stock worth over $174,900 and over the last 9 years Louis sold PIRS stock worth over $0.
Louis has made over 2 trades of the Pieris Pharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Louis bought 10,000 units of PIRS stock worth $17,000 on 13 June 2016.
The largest trade Louis's ever made was buying 10,000 units of Pieris Pharmaceuticals Inc stock on 13 June 2016 worth over $17,000. On average, Louis trades about 3,333 units every 0 days since 2015. As of 13 June 2016 Louis still owns at least 10,000 units of Pieris Pharmaceuticals Inc stock.
You can see the complete history of Louis Matis stock trades at the bottom of the page.
Louis's mailing address filed with the SEC is 255 State St 9th floor, Boston, MA 02109, USA.
Over the last 9 years, insiders at Pieris Pharmaceuticals Inc have traded over $24,745,707 worth of Pieris Pharmaceuticals Inc stock and bought 1,154,000 units worth $3,376,410 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Advisors Llc Orbi Med Capit... et Chau Quang Khuong. On average, Pieris Pharmaceuticals Inc executives and independent directors trade stock every 144 days with the average trade being worth of $4,572,148. The most recent stock trade was executed by Capital Management, Llcadar... on 9 August 2024, trading 6,000 units of PIRS stock currently worth $92,340.
pieris pharmaceuticals is a clinical stage biotechnology company that discovers and develops anticalin-based drugs to target validated disease pathways in a unique and transformative way. our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled anticalin to treat uncontrolled asthma and a half-life-optimized anticalin to treat anemia. proprietary to pieris, anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. our libraries of more than 100 billion different anticalin proteins have repeatedly delivered drug candidates binding to a very broad spectrum of therapeutic targets. pieris has established a diverse pipeline of anticalin therapeutics for a number of different indications and has r&d collaborations with roche
Pieris Pharmaceuticals Inc executives and other stock owners filed with the SEC include: